Find therapeutics

Find Therapeutics is a clinical-stage biopharmaceutical company headquartered in Montreal, Canada, that was established in 2020. The company is focused on creating and advancing therapies for inflammatory autoimmune diseases.

The company was launched with initial investments from CTI Life Sciences, adMare BioInnovations, and Domain Therapeutics. It also secured an exclusive license from the University of Strasbourg and SATT-Conectus for a technology developed by Dr. Dominique Bagnard, a professor at the University of Strasbourg and an expert in neurobiology and brain diseases. Dr. Bagnard, who invented the company's core myelin repair technology, serves as a key strategic advisor, shaping the scientific and development strategy. The company's President and CEO, Philippe Douville, brings 25 years of experience in the biotechnology sector, including his role as the founding CEO of Milestone Pharmaceuticals.

Find Therapeutics' business model revolves around its drug discovery and development pipeline. The company utilizes a peptide discovery engine to create peptides that target transmembrane domains of receptors involved in critical biological processes. Its revenue generation is linked to the successful progression of its therapeutic candidates through clinical trials and eventual commercialization. The company has successfully raised capital to fund its operations, including an $8.1 million convertible note financing in September 2024 to advance its lead product into Phase 1 clinical studies. Key investors include CTI Life Sciences Fund, adMare BioInnovations, Domain Therapeutics, and Investissement Québec.

The company’s lead product is FTX-101, a remyelinating agent designed to restore vision in individuals affected by Chronic Optic Neuropathy (CON). This therapeutic peptide targets a receptor complex in the brain (Plexin A1 and Neuropilin 1) that is involved in the creation of myelinating oligodendrocytes, which are crucial for nerve fiber protection. In October 2024, Find Therapeutics initiated a Phase 1 clinical trial for FTX-101 to assess its safety, tolerability, and pharmacokinetics in healthy volunteers, following clearance from the U.S. Food and Drug Administration (FDA). Beyond FTX-101, the company's pipeline includes discovery programs focused on GPCR modulators for gastrointestinal diseases.

Keywords: biopharmaceutical, autoimmune diseases, myelin repair, peptide therapies, clinical-stage, neurobiology, drug discovery, transmembrane peptides, inflammatory diseases, Chronic Optic Neuropathy, FTX-101, remyelination, GPCR modulators, venture capital, CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, Investissement Québec, Phase 1 clinical trial, peptide discovery engine, neuroprotection